Company: PTPI
Filing Date: 2025-02-10
Form Type: S-1/A
Source: 0001410578-25-000108
Chunk: 262

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-10
Form: S-1/A
Chunk 262
---
ings to customers representing 10% or more of the Company’s total gross billings included customers which represented approximately %, %, and % of total gross billings, respectively. For the three months ended

F-42

September 30, 2024, gross billings to customers representing 10% or more of the Company’s total gross billings included threecustomers which represented approximately 30%, 25%, and 14% of total gross billings, respectively. For the three months ended September 30, 2023, gross billings to customers representing 10% or more of the Company’s total gross billings included threecustomers which represented approximately 24%, 21%, and 18% of total gross billings, respectively. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included threecustomers at September 30, 2024, equal to 53%, 25%, and 22%, respectively. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included threecustomers at December 31, 2023, equal to 36%, 24% and 16%, respectively. Effective November 1, 2024, the Company determined to discontinue sales of Stendra® to wholesalers to mitigate the risk of returns associated with expired or near-expired prescription medication due to Stendra® having less than a six-month shelf life. Sales of Stendra® to wholesalers collectively accounted for approximately 94% and 95% of net sales for the three months ended and nine months ended September 30, 2024, respectively.

4) Inventories

Inventory is comprised of the following:

| ​               | ​ 
 ​ | ​ |                  ​ 
 September 30, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:----------------|:--|:--|-------------------:|:--|:--|------------------:|
| Raw Materials   | ​ | $ |          1,257,152 | ​ | $ |         1,430,139 |
| Finished goods  | ​ |   |            148,499 | ​ | ​ |           180,252 |
| Total inventory | ​ | $ |          1,405,651 | ​ | $ |         1,610,391 |

Finished goods are net of valuation reserves of $ and $ as